›› 2017, Vol. 37 ›› Issue (11): 1524-.doi: 10.3969/j.issn.1674-8115.2017.11.013

Previous Articles     Next Articles

Efficacy of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR 21L861Q mutation#br#

HU Zhang-guo, CAO Shu-hui, ZHONG Hua   

  1. Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
  • Online:2017-11-28 Published:2018-01-10
  • Supported by:
     Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20161434; Foundation of Shanghai Chest Hospital, YZ2015-ZX12

Abstract: Objective · To evaluate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in non small cell lung cancer (NSCLC) patients with uncommon EGFR 21L861Q mutation.  Methods · Between June 2011 and Marth 2015, clinical data of 21 stage Ⅲ B/ Ⅳ NSCLC patients who received EGFR-TKI harboring uncommon 21L861Q mutation in EGFR at the Shanghai Chest Hospital were collected. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS ) and overall survival (OS ) of the patients under TKI therapy were retrospectively analyzed.  Results · ORR and DCR of the patients under TKIs therapy (first-line+second-line+third-line) were 42.9% and 66.7% respectively. PFS and OS of patients who received therapy that consisted of EGFR-TKIs (first-line+second-line+third-line) were 7.03 months (95% CI, 5.50-8.69) and 22.80 months (95% CI, 16.22-25.65).  Conclusion · Our post-hoc analyses demonstrated that EGFR-TKIs showed activity in patients with uncommon EGFR 21L861Q-mutant NSCLC, less effective than in those with common mutations.

Key words: non small cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR uncommon mutations, 21L861Q

CLC Number: